Cargando…

Broad-spectrum therapeutics: A new antimicrobial class

There are currently no emergency treatments for pandemics, yet drug repositioning has emerged as the foremost treatment development strategy for COVID-19, with an aim to identify successful antiviral therapeutics from safe, non-antiviral candidates. These therapeutics include antibiotics such as azi...

Descripción completa

Detalles Bibliográficos
Autores principales: Firth, Anton, Prathapan, Praveen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035643/
https://www.ncbi.nlm.nih.gov/pubmed/34870144
http://dx.doi.org/10.1016/j.crphar.2020.100011
_version_ 1783676742994493440
author Firth, Anton
Prathapan, Praveen
author_facet Firth, Anton
Prathapan, Praveen
author_sort Firth, Anton
collection PubMed
description There are currently no emergency treatments for pandemics, yet drug repositioning has emerged as the foremost treatment development strategy for COVID-19, with an aim to identify successful antiviral therapeutics from safe, non-antiviral candidates. These therapeutics include antibiotics such as azithromycin and the antiparasitic nitazoxanide, both of which exhibit antiviral activity. Broad-spectrum therapeutics (BSTs) are a class of antimicrobials active against multiple pathogen types. Establishment of a developmental framework for BSTs will markedly improve global preparedness for future health emergencies.
format Online
Article
Text
id pubmed-8035643
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80356432021-04-12 Broad-spectrum therapeutics: A new antimicrobial class Firth, Anton Prathapan, Praveen Curr Res Pharmacol Drug Discov Review Article There are currently no emergency treatments for pandemics, yet drug repositioning has emerged as the foremost treatment development strategy for COVID-19, with an aim to identify successful antiviral therapeutics from safe, non-antiviral candidates. These therapeutics include antibiotics such as azithromycin and the antiparasitic nitazoxanide, both of which exhibit antiviral activity. Broad-spectrum therapeutics (BSTs) are a class of antimicrobials active against multiple pathogen types. Establishment of a developmental framework for BSTs will markedly improve global preparedness for future health emergencies. Elsevier 2020-12-11 /pmc/articles/PMC8035643/ /pubmed/34870144 http://dx.doi.org/10.1016/j.crphar.2020.100011 Text en Crown Copyright © 2020 Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Firth, Anton
Prathapan, Praveen
Broad-spectrum therapeutics: A new antimicrobial class
title Broad-spectrum therapeutics: A new antimicrobial class
title_full Broad-spectrum therapeutics: A new antimicrobial class
title_fullStr Broad-spectrum therapeutics: A new antimicrobial class
title_full_unstemmed Broad-spectrum therapeutics: A new antimicrobial class
title_short Broad-spectrum therapeutics: A new antimicrobial class
title_sort broad-spectrum therapeutics: a new antimicrobial class
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035643/
https://www.ncbi.nlm.nih.gov/pubmed/34870144
http://dx.doi.org/10.1016/j.crphar.2020.100011
work_keys_str_mv AT firthanton broadspectrumtherapeuticsanewantimicrobialclass
AT prathapanpraveen broadspectrumtherapeuticsanewantimicrobialclass